Ovid Therapeutics (ticker: OVID) grants CFO 50,000 RSUs vesting 2027-2028

Rhea-AI Filing Summary

Carter Charles Ross reported acquisition or exercise transactions in this Form 4 filing.

Ovid Therapeutics Inc. reported that Chief Financial Officer Charles Ross received a grant of 50,000 restricted stock units (RSUs) of common stock on July 6, 2026 as equity compensation. Each RSU represents a contingent right to receive one share of common stock at no purchase price.

The RSUs will vest in two equal annual installments beginning on July 6, 2027, subject to Ross’s continuous service through each vesting date. Following this award, Ross directly holds 94,375 shares of Ovid common stock, reflecting his equity stake in the company.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Carter Charles Ross

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	50,000	$0.00	--

Holdings After Transaction: Common Stock — 94,375 shares (Direct)

Footnotes (1)

1. Represents a restricted stock unit ("RSU") award. The RSUs will vest in two equal annual installments commencing on July 6, 2027, subject to the Reporting Person's continuous service through each such vesting date. Each RSU represents a contingent right to receive one share of Common Stock.

Key Figures

RSU award size: 50,000 RSUs Vesting schedule: Two equal annual installments Price per RSU: $0.00 per share +1 more

4 metrics

RSU award size 50,000 RSUs Grant to CFO on July 6, 2026

Vesting schedule Two equal annual installments Commencing July 6, 2027

Price per RSU $0.00 per share Equity compensation grant

Shares held after grant 94,375 shares CFO direct common stock ownership following award

Key Terms

restricted stock unit ("RSU"), contingent right, continuous service

3 terms

restricted stock unit ("RSU") financial

"Represents a restricted stock unit ("RSU") award."

contingent right financial

"Each RSU represents a contingent right to receive one share of Common Stock."

continuous service financial

"subject to the Reporting Person's continuous service through each such vesting date."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/08/2026 - 04:32 PM Accepted by SEC EDGAR 07/08/2026 - 04:31 PM Learn about SEC filing dates

FAQ

What did Ovid Therapeutics (OVID) disclose about its CFO’s recent equity award?

Ovid Therapeutics disclosed that CFO Charles Ross received 50,000 restricted stock units on July 6, 2026. These RSUs are equity compensation and each unit represents a contingent right to receive one share of Ovid common stock at no purchase price.

How do the CFO’s 50,000 OVID RSUs vest over time?

The 50,000 RSUs granted to Ovid’s CFO vest in two equal annual installments starting July 6, 2027. Vesting is conditioned on Charles Ross maintaining continuous service with the company through each applicable vesting date.

What does each RSU granted to the OVID CFO represent?

Each RSU granted to Ovid’s CFO represents a contingent right to receive one share of Ovid common stock. The shares are delivered as the RSUs vest and do not require Ross to pay a purchase price per share.

How many OVID shares does the CFO hold after this RSU grant?

After the RSU grant, Ovid’s CFO Charles Ross directly holds 94,375 shares of Ovid common stock. This figure reflects his reported direct ownership following the 50,000-unit restricted stock award on July 6, 2026.

Is the OVID CFO’s 50,000 RSU award a market purchase of shares?

No, the 50,000 RSUs awarded to Ovid’s CFO are not a market purchase. They are a grant of restricted stock units with a $0.00 grant price, forming part of his equity-based compensation package rather than an open-market buy.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Carter Charles Ross

(Last) (First) (Middle)

C/O OVID THERAPEUTICS INC.

441 NINTH AVENUE, 14TH FLOOR

(Street)

NEW YORK NEW YORK 10001

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Ovid Therapeutics Inc. [ OVID ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/06/2026		A		50,000(1)	A	$0(2)	94,375	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a restricted stock unit ("RSU") award. The RSUs will vest in two equal annual installments commencing on July 6, 2027, subject to the Reporting Person's continuous service through each such vesting date.

2. Each RSU represents a contingent right to receive one share of Common Stock.

	/s/ Charles Carter	07/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)